Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
References
Additional references
Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. Journal of Clinical Virology 2007;38(3):189‐97.
Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Annals of Oncology 2011;22:2675‐86.
Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 2004;22(0264‐410X, 23‐24):3004‐7.
Ault KA. Effect of prophylactic human papillomavirus L1 virus‐like‐particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369(9576):1861‐8.
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002;55:244‐65.
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens‐Part B: biological agents. Lancet Oncology 2009;10(1474‐5488 (Electronic), 4):321‐2.
Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiology, Biomarkers and Prevention 2005;14(9):2191‐9.
Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiology, Biomarkers and Prevention 2005;14(1055‐9965, 3):677‐86.
Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin‐Dinh‐Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. Journal of Virology 1995;69(6):3959‐63.
Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM, et al. Neutralization of human papillomavirus type 11 (HPV‐11) by serum from women vaccinated with yeast‐derived HPV‐11 L1 virus‐like particles: correlation with competitive radioimmunoassay titer. Journal of Infectious Diseases 2001;184(9):1183‐6.
Castellsague X, Diaz M, De Sanjose S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. Journal of the National Cancer Institute 2006;98(1460‐2105 (Electronic), 5):303‐15.
Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncology . 2005;6(1470‐2045, 4):204.
De Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta‐analysis. Lancet Infectious Diseases . 2007;7(1473‐3099 (Print), 7):453‐9.
Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta‐Analysis in Context (2nd edition). London: BMJ Publication Group, 2001.
DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88 177‐188.
Dorans K. Fewer shots proposed to increase uptake of HPV vaccine. Nature Medicine 2010;16:832‐833.
Eggertson L. Three provinces to study 2‐dose HPV vaccine. Canadian Medical Association Journal . 2007;177(1488‐2329 (Electronic), 5):444‐5.
Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. Journal of Infectious Diseases . 2001;183(0022‐1899, 10):1485‐93.
Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. Lyon: IARCPress, 2004.
Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nature Reviews Immunology 2004;4:46‐55.
Galloway DA. Papillomavirus vaccines in clinical trials. Lancet 2003;3:469‐75.
Ghim S, Newsome J, Bell J, Sundberg JP, Schlegel R, Jenson AB. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Experimental and Molecular Pathology 2000;68(3):147‐51.
Harper DM. Currently approved prophylactic HPV vaccines. Expert Review of Vaccines 2009;8(12):1663‐79.
Harro CD, Pang Y‐YS, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 Virus‐Like particle vaccine. Journal of National Cancer Institute . 2001;93(4):284‐92.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration2008, issue Version 5.0.1:www.cochrane‐handbook.org.
IARC Expert team cervical cancer screening, (Day N, Hakama M, Arbyn M). Cervix Cancer Screening. IARC Handbooks of Cancer Prevention. Vol. 10, Lyon: IARC Press, 2005.
IARC Monograph Working Group on Carcinogenesis (Coglinano V, Baan R, Straif K, Secretan B, El Ghissasi F, Zur Hausen H, et al) . In: Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi F editor(s). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses. Vol. 90, Lyon: IARC Press, 2007:1‐670.
Iftner T, Villa LL. Chapter 12: Human papillomavirus technologies. Journal of National Cancer Institute Monographs 2003;2003(31):80‐8.
Initiative for Vaccine Research of the Department of Immunization VaB. Human Papillomavirus (HPV) Vaccine Background Paper. World Health Organization (WHO). Geneva, 2009:1‐249.
Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. New England Journal of Medicine 2009;361(3):271‐8.
Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high‐grade cervical and external genital lesions. Cancer Prvention Research 2009;2(10):868‐78.
Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB. A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine 2002;347:1645‐51.
Koutsky LA, Harper DM. Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine 2006;24(Suppl 3):114‐21.
Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non‐cancerous HPV‐related conditions: HPV‐6/11 disease. Vaccine 2006;24(0264‐410X (Print), Suppl 3):35‐41.
McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncology 2008;9(5):425‐34.
Medeiros LR, Rosa DD, Da Rosa MI, Bozzetti MC, Zanini RR. Efficacy of human papillomavirus vaccines: a systematic quantitative review. International Journal of Gynecological Cancer 2009;19(7):1166‐76.
Munoz N, Bosch FX, Castellsague X, Diaz M, De Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. International Journal of Cancer 2004;111:278‐85.
Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. International Journal of Gynegological Pathology 1993;12(2):186‐92.
Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23(0264‐410X, 5):569‐78.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34.
Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. Canadian Medical Association Journal 2007;177(5):469‐79.
Richart RM. Cervical intraepithelial neoplasia. Pathology Annual 1973;8:301‐23.
Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE‐4. Survival of cancer patients diagnosed in 1995‐1999. Results and commentary. European Journal of Cancer 2009;45(6):931‐91.
Schiffman MA, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337(0042‐6822, 1):76‐84.
Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infectious Agents and Cancer2009; Vol. 4, issue 1:(1‐8).
Schneider A, Gissmann L. Cervical cancer. The potential role of human papillomavirus (HPV)‐specific vaccines in prevention and treatment. American Journal of Cancer 2003;2:1‐253.
Sharp S. Meta‐analysis regression. Statatistics Technical Bulletin 1998;7(42):148‐55. [MEDLINE: 11989]
Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States‐‐a 24‐year population‐based study. Gynecologic Oncology2000; Vol. 78, issue 2:97‐105.
Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114‐9.
Stanley MA. Human papillomavirus vaccines. Reviews in Medical Virology 2006;16(1052‐9276 (Print), 3):139‐49.
Szarewski A. HPV vaccine: Cervarix. Expert Opinion on Biological Therapy 2010;10(3):477‐87.
Thompson SG, Sharp SJ. Explaining heterogeneity in meta‐analysis: a comparison of methods. Statistics in Medicine 1999;18(20):2693‐708. [MEDLINE: 11967]
Initiative for Vaccine Research of the Department of Immunization Vaccines and Biologicals (WHO). Human Papillomavirus (HPV) Vaccine Background Paper. World Health Organization (WHO)2009:1‐249.
Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Journal of Epidemiology . 2003;157:218‐26.
Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner. Journal of Infectious Diseases 2008;197(0022‐1899 (Print), 2):279‐82.
Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang Z‐F. Cervical cancer as a priority for prevention in different world regions : an evaluation using years of life lost. Internaional Journal of Cancer 2004;109:418‐24.
